Targeted therapies with immunotherapies in kidney cancer
The following video is an interview with Professor Thomas Powles [...]
Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
Dalantercept plus axitinib combination for advanced kidney cancer
The results from a recent phase II study comparing a [...]
Patients may not be able to tolerate recommended dose of cabozantinib
A recent study published on Oncology this month suggests that [...]
First immunotherapy combination of ipilimumab plus nivolumab available to patients in England
We are very pleased to learn that the ipilimumab plus [...]
HIF-2α inhibitor shows promise in patients with advanced kidney cancer
A recent phase I/II clinical trial with PT2977, a hypoxia-inducible [...]
Bevacizumab plus erlotinib combination for advanced HLRCC
A recent study, published in Cancer Research and Treatment in [...]
Personalised in vitro model to help screen drugs for kidney cancer
Researchers at the University of Wisconsin Carbone Cancer Center in [...]
The hunt for a kidney cancer biomarker reveals two more potential candidates
As the hunt for a reliable biomarker for renal cell [...]
Anlotinib versus sunitinib as first-line treatment for metastatic kidney cancer
The results of a recent phase 2 study to evaluate [...]
